FDA Approval: Sipuleucel-T (Provenge) for Prostate Cancer

What the license covers

The FDA licensed PROVENGE, generic name sipuleucel-T, under STN BL 125197. The package insert gives the initial US approval year as 2010. The original manufacturer was Dendreon Corporation.

FDA's own product page states the indication in one sentence: for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant, also called hormone refractory, prostate cancer.

Every word in that sentence narrows it. Metastatic means the cancer has spread beyond the prostate. Castrate resistant means it is still growing even though testosterone has been driven down by drugs or surgery. Asymptomatic or minimally symptomatic means the person is not in significant pain from it. Our page on metastatic prostate cancer explains that setting.

Why it is not a drug off a shelf

Sipuleucel-T is made from the patient's own cells. It is autologous, meaning each dose belongs to one person and no one else.

NCI describes the process. Immune cells are collected from the blood by leukapheresis, a procedure that filters white cells out and returns the rest. Those cells are then exposed outside the body to a laboratory-made fusion protein called PA2024, which joins prostatic acid phosphatase, a protein found on prostate cells, to GM-CSF, a signal that activates immune cells. The cells are shipped back and infused.

The label sets the schedule: three doses at roughly two-week intervals, each infused over about 60 minutes, with acetaminophen and an antihistamine given beforehand. There is no cell filter. Staff must confirm the patient's identity against the bag, because the product is specific to one person.

The label also notes that the product is not routinely tested for transmissible infectious diseases and may transmit them to staff handling it, so universal precautions apply.

The evidence

The pivotal study was the IMPACT trial. NCI records that 512 men with hormone-refractory metastatic disease were randomly assigned 2:1 to sipuleucel-T (341 men) or placebo (171 men). Men with visceral metastases, broken bones from the cancer, or poorer performance status were excluded. The label adds that men needing narcotics for cancer pain were also excluded, and that the median age was 71.

The label's own table gives the result. Median overall survival was 25.8 months with sipuleucel-T against 21.7 months with control, a hazard ratio of 0.775. In a smaller supportive study of 127 men, the medians were 25.9 and 21.4 months.

NCI adds the detail that matters most for interpretation. After a median follow-up of 34.1 months, overall mortality was 61.6% in the treated group and 70.8% in the control group. But the survival difference came without measurable antitumor effects: there was no difference between the groups in how fast the disease progressed.

The primary endpoint was also changed before the study was unblinded, from time to progression to survival, based on results from two earlier trials of similar design. Those two earlier trials, covering 225 men, gave a hazard ratio for death of 0.67.

What it costs, and what it does not do

NCI cites a 2011 estimate that put the price at $93,000 for a one-month course, which worked out at roughly $276,000 per year of life gained.

The most common side effects, at 15% or more, are chills, fatigue, fever, back pain, nausea, joint ache, and headache. NCI describes these as consistent with cytokine release and usually appearing in the first 24 hours after an infusion. The label warns about acute infusion reactions and says to monitor people with heart or lung conditions closely. NCI notes no rise in autoimmune disorders or second cancers.

The label carries no contraindications, and states that using it alongside chemotherapy or immune-suppressing drugs has not been studied.

When to get checked

This treatment is for men who already have a diagnosis. These are the symptoms that should prompt an appointment before any of that:

• Trouble starting or stopping urination, or a weak stream
• Passing urine much more often, especially at night
• Blood in the urine or semen
• New, persistent pain in the back, hips, or pelvis
• Unexplained weight loss alongside any of the above

For men already treated for prostate cancer, a PSA level that keeps rising is the usual first sign that something has changed. Our page on what a rising PSA means covers that conversation.

What this does not mean

• The indication is narrow. It covers metastatic, castrate-resistant disease in men with no or minimal symptoms. It is not a treatment for early prostate cancer.
• A four-month difference in median survival describes the middle of a distribution. Individual results in the trial ranged widely.
• The trial found no difference in how fast the disease progressed. Tumors were not measurably shrinking; the survival curves still separated.
• Men with visceral metastases, cancer-related fractures, or significant cancer pain were excluded, so the trial says nothing about them.
• The $93,000 figure is a 2011 estimate cited by NCI. Current price, coverage, and access are separate questions for a care team and an insurer.

Sources

• FDA CBER, PROVENGE (sipuleucel-T), STN BL 125197 — https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/provenge-sipuleucel-t
• FDA, PROVENGE (sipuleucel-T) package insert — https://www.fda.gov/media/78511/download?attachment
• NCI PDQ, Prostate Cancer Treatment (Health Professional Version) — https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
• NCI, Prostate Cancer—Patient Version — https://www.cancer.gov/types/prostate

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.